Dupilumab sustains efficacy in patients with moderate-to-severe type 2
asthma regardless of ICS dose
Background: Dupilumab, a human monoclonal antibody, blocks the
shared receptor component for interleukins 4/13, key and central drivers
of type 2 inflammation. The LIBERTY ASTHMA TRAVERSE (NCT02134028)
open-label extension study demonstrated the long-term safety and
efficacy of dupilumab in patients ≥12 years who had participated in a
previous dupilumab asthma study. The safety profile was consistent with
that observed in the parent studies. Methods: This analysis
includes patients from phase 2b (NCT01854047) or phase 3 (QUEST;
NCT02414854) studies receiving high- or medium-dose inhaled
corticosteroids (ICS) at parent study baseline (PSBL) and enrolled in
TRAVERSE. We analyzed unadjusted annualized severe exacerbation rates,
change from PSBL in pre-bronchodilator (pre-BD) FEV 1
(L), asthma control (5-item asthma control questionnaire), and type 2
biomarkers in patients with type 2 asthma at baseline (blood eosinophils
≥150 cells/µL or fractional exhaled nitric oxide [FeNO] ≥25 ppb),
and subgroups defined by baseline blood eosinophils or FeNO.
Results: Of patients with type 2 asthma (n=1,666) in this
analysis, 891 (53.5%) were receiving high‑dose ICS at PSBL. In this
subgroup, unadjusted exacerbation rates for dupilumab vs placebo were
0.517 vs. 1.883 (phase 2b) and 0.571 vs. 1.300 (QUEST) over 52 weeks of
the parent study, and remained low throughout TRAVERSE (0.313–0.494).
Improvements in pre-BD FEV 1 from PSBL were sustained
throughout TRAVERSE. Similar clinical efficacy was observed among
patients receiving medium-dose ICS at PSBL and biomarker subgroups.
Conclusions: Dupilumab showed sustained efficacy for up to 3
years in patients with uncontrolled, moderate-to-severe type 2 asthma on
high- or medium-dose ICS.